Literature DB >> 32016000

PD-1 inhibition: a novel approach to the treatment of progressive multifocal leukoencephalopathy.

Joseph R Berger1.   

Abstract

Year:  2019        PMID： 32016000      PMCID： PMC6976511          DOI： 10.21037/atm.2019.11.107

Source DB:  PubMed          Journal:  Ann Transl Med        ISSN： 2305-5839


× No keyword cloud information.
  24 in total

1.  Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy.

Authors:  Irene Cortese; Pawel Muranski; Yoshimi Enose-Akahata; Seung-Kwon Ha; Bryan Smith; MariaChiara Monaco; Caroline Ryschkewitsch; Eugene O Major; Joan Ohayon; Matthew K Schindler; Erin Beck; Lauren B Reoma; Steve Jacobson; Daniel S Reich; Avindra Nath
Journal:  N Engl J Med       Date:  2019-04-10       Impact factor: 91.245

2.  Treatment of Progressive Multifocal Leukoencephalopathy with Pembrolizumab.

Authors:  Sebastian Rauer; Reinhard Marks; Horst Urbach; Klaus Warnatz; Avindra Nath; Steve Holland; Cornelius Weiller; Bodo Grimbacher
Journal:  N Engl J Med       Date:  2019-04-10       Impact factor: 91.245

3.  Treatment of Progressive Multifocal Leukoencephalopathy with Nivolumab.

Authors:  Ondine Walter; Emmanuel Treiner; Fabrice Bonneville; Catherine Mengelle; François Vergez; Fleur Lerebours; Pierre Delobel; Roland Liblau; Guillaume Martin-Blondel
Journal:  N Engl J Med       Date:  2019-04-10       Impact factor: 91.245

4.  Severe relapse in a multiple sclerosis patient associated with ipilimumab treatment of melanoma.

Authors:  Edward J Gettings; Christopher T Hackett; Thomas F Scott
Journal:  Mult Scler       Date:  2014-09-25       Impact factor: 6.312

Review 5.  Multiple sclerosis outcomes after cancer immunotherapy.

Authors:  Catherine R Garcia; Rani Jayswal; Val Adams; Lowell B Anthony; John L Villano
Journal:  Clin Transl Oncol       Date:  2019-02-20       Impact factor: 3.405

6.  Human polyomavirus JC virus genome.

Authors:  R J Frisque; G L Bream; M T Cannella
Journal:  J Virol       Date:  1984-08       Impact factor: 5.103

Review 7.  Classifying PML risk with disease modifying therapies.

Authors:  Joseph R Berger
Journal:  Mult Scler Relat Disord       Date:  2017-01-06       Impact factor: 4.339

Review 8.  Progressive multifocal leukoencephalopathy: current treatment options and future perspectives.

Authors:  Dejan Pavlovic; Andriani C Patera; Fredrik Nyberg; Marianne Gerber; Maggie Liu
Journal:  Ther Adv Neurol Disord       Date:  2015-11       Impact factor: 6.570

9.  The Incidence and Predisposing Factors of John Cunningham Virus-Induced Progressive Multifocal Leukoencephalopathy in Southern Finland: A Population-Based Study.

Authors:  Marge Kartau; Auli Verkkoniemi-Ahola; Anders Paetau; Maarit Palomäki; Rita Janes; Matti Ristola; Maija Lappalainen; Veli-Jukka Anttila
Journal:  Open Forum Infect Dis       Date:  2019-02-22       Impact factor: 3.835

10.  A study of mefloquine treatment for progressive multifocal leukoencephalopathy: results and exploration of predictors of PML outcomes.

Authors:  David B Clifford; Avindra Nath; Paola Cinque; Bruce J Brew; Robert Zivadinov; Leonid Gorelik; Zhenming Zhao; Petra Duda
Journal:  J Neurovirol       Date:  2013-06-04       Impact factor: 2.643
View more
  2 in total

1.  Single-Dose Pembrolizumab Treatment for Progressive Multifocal Leukoencephalopathy.

Authors:  Martijn Beudel; Fleur Rövekamp; Diederik van de Beek; Matthijs Brouwer
Journal:  Neurol Neuroimmunol Neuroinflamm       Date:  2021-05-26

Review 2.  The Anti-PD-1/PD-L1 Immunotherapy for Gastric Esophageal Cancer: A Systematic Review and Meta-Analysis and Literature Review.

Authors:  Ke Chen; Xiao Wang; Liu Yang; Zheling Chen
Journal:  Cancer Control       Date:  2021 Jan-Dec       Impact factor: 3.302
  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.